NASDAQ:TSHA

Taysha Gene Therapies Stock Forecast, Price & News

$23.86

-1.05 (-4.22 %)

(As of 04/16/2021 12:00 AM ET)

Add

Compare

Today's Range

$23.39

Now: $23.86▼

$25.32

50-Day Range

$19.29

MA: $23.75▼

$29.36

52-Week Range

$18.16

Now: $23.86▼

$33.35

Volume89,203 shs

Average Volume91,715 shs

Market Capitalization$900.98 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:TSHA

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.tayshagtx.com

Phone214-612-0000

Employees38

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio24.02

Quick Ratio24.02

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares37,761,000

Market Cap$900.98 million

Next Earnings Date6/2/2021 (Estimated)

OptionableNot Optionable

Headlines

Taysha Gene Therapies (NASDAQ:TSHA) Sees Large Volume Increase
April 15, 2021 | americanbankingnews.com

Oppenheimer Analysts Cut Earnings Estimates for Taysha Gene Therapies, Inc. (NASDAQ:TSHA)
April 15, 2021 | americanbankingnews.com

William Blair Weighs in on Taysha Gene Therapies, Inc.'s Q1 2021 Earnings (NASDAQ:TSHA)
April 15, 2021 | americanbankingnews.com

BRIEF-Taysha Gene Therapies Announces New Data On Multiple Preclinical Programs And Upcoming Research And Development Day
April 14, 2021 | msn.com

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 4.8% After Analyst Upgrade
April 13, 2021 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) PT Raised to $43.00 at Morgan Stanley
April 13, 2021 | americanbankingnews.com

Taysha Gene Therapies Stock Is Trading Higher After Buying Rights To New Gene Therapy Candidate For Neurodegenerative Disease
April 12, 2021 | finance.yahoo.com

Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $67.50 at Chardan Capital
April 12, 2021 | americanbankingnews.com

Why Taysha Gene Therapies's Stock is Trading Higher Today
April 12, 2021 | msn.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up to $21.19
April 12, 2021 | americanbankingnews.com

BRIEF-Taysha Gene Therapies Acquires Exclusive Worldwide Rights To Clinical-Stage Aav9 Gene Therapy Program, Now Known As Tsha-120, For Giant Axonal Neuropathy
April 12, 2021 | msn.com

Taysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program, Now Known as TSHA-120, for the Treatment of Giant Axonal Neuropathy, a Rare and Severe Neurodegenerative Disease
April 12, 2021 | finance.yahoo.com

Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences
April 5, 2021 | finance.yahoo.com

Financial Review: Surface Oncology (NASDAQ:SURF) versus Taysha Gene Therapies (NASDAQ:TSHA)
March 30, 2021 | americanbankingnews.com

Brokerages Expect Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Will Post Earnings of -$0.45 Per Share
March 30, 2021 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $21.54
March 29, 2021 | americanbankingnews.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by Brokerages
March 29, 2021 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up to $22.47
March 25, 2021 | americanbankingnews.com

Here's Why We're Not Too Worried About Taysha Gene Therapies' (NASDAQ:TSHA) Cash Burn Situation
March 24, 2021 | finance.yahoo.com

Taysha Gene Therapies (NASDAQ:TSHA) Sees Unusually-High Trading Volume
March 24, 2021 | americanbankingnews.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.77 out of 5 stars

Medical Sector

175th out of 2,025 stocks

Biological Products, Except Diagnostic Industry

23rd out of 177 stocks

3.5 Analyst's Opinion

Consensus Rating
Taysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $43.92, Taysha Gene Therapies has a forecasted upside of 84.1% from its current price of $23.86.
Amount of Analyst Coverage
Taysha Gene Therapies has only been the subject of 3 research reports in the past 90 days.

3.9 Community Rank

Outperform Votes
Taysha Gene Therapies has received 14 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Taysha Gene Therapies has received 4 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Taysha Gene Therapies has received 77.78% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Taysha Gene Therapies and other stocks. Vote “Outperform” if you believe TSHA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TSHA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Taysha Gene Therapies does not currently pay a dividend.
Dividend Growth
Taysha Gene Therapies does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Taysha Gene Therapies insiders have not sold or bought any company stock.
Percentage Held by Institutions
42.19% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Taysha Gene Therapies are expected to grow in the coming year, from ($3.19) to ($1.54) per share.

See Top Rated MarketRank™ Stocks Here

$23.86

-1.05 (-4.22 %)

(As of 04/16/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive TSHA News and Ratings via Email

Sign-up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter.

Taysha Gene Therapies (NASDAQ:TSHA) Frequently Asked Questions

Is Taysha Gene Therapies a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taysha Gene Therapies in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Taysha Gene Therapies stock.
View analyst ratings for Taysha Gene Therapies or view top-rated stocks.

What stocks does MarketBeat like better than Taysha Gene Therapies?

Wall Street analysts have given Taysha Gene Therapies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Taysha Gene Therapies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Taysha Gene Therapies' next earnings date?

Taysha Gene Therapies is scheduled to release its next quarterly earnings announcement on Wednesday, June 2nd 2021.
View our earnings forecast for Taysha Gene Therapies.

How were Taysha Gene Therapies' earnings last quarter?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) posted its quarterly earnings results on Tuesday, March, 2nd. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.36) by $0.68.
View Taysha Gene Therapies' earnings history.

What price target have analysts set for TSHA?

6 equities research analysts have issued 1 year price targets for Taysha Gene Therapies' stock. Their forecasts range from $31.00 to $67.50. On average, they anticipate Taysha Gene Therapies' stock price to reach $43.92 in the next twelve months. This suggests a possible upside of 84.1% from the stock's current price.
View analysts' price targets for Taysha Gene Therapies or view top-rated stocks among Wall Street analysts.

Who are Taysha Gene Therapies' key executives?

Taysha Gene Therapies' management team includes the following people:

Mr. R. A. Session II, Founder, Pres, CEO & Director (Age 42, Pay $634.63k)
Mr. Kamran Alam CPA, M.B.A., Chief Financial Officer (Age 43, Pay $756.38k)
Dr. Suyash Prasad FFPM, M.Sc., MBBS, M.D., M.B.B.S., F.F.P.M, Chief Medical Officer and Head of R&D (Age 51, Pay $501.78k)
Mr. Fred Porter Ph.D., Chief Technical Officer
Mr. Jim Rouse, Chief Information Officer
Dr. Kimberly Lee D.O., Sr. VP of Corp. Communications & Investor Relations
Mr. Timothy J. Douros J.D., Chief Legal Officer & Corp. Sec.
Ms. Tracy M. Porter, Chief People Officer
Ms. Emily McGinnis M.P.H., Chief Patient Officer & Head of Gov. Affairs
Ms. Mishima Gerhart, Chief Regulatory Officer & Head of Quality

Who are some of Taysha Gene Therapies' key competitors?

Some companies that are related to Taysha Gene Therapies include SpringWorks Therapeutics (SWTX), NanoString Technologies (NSTG), Revolution Medicines (RVMD), Relay Therapeutics (RLAY), Bavarian Nordic A/S (BVNRY), Vericel (VCEL), Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), BioCryst Pharmaceuticals (BCRX), Rubius Therapeutics (RUBY), bluebird bio (BLUE), NantKwest (NK), Kymera Therapeutics (KYMR), Krystal Biotech (KRYS) and Sangamo Therapeutics (SGMO).
View all of TSHA's competitors.

When did Taysha Gene Therapies IPO?

(TSHA) raised $125 million in an initial public offering (IPO) on Thursday, September 24th 2020. The company issued 6,600,000 shares at $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies served as the underwriters for the IPO and Chardan was co-manager.

What is Taysha Gene Therapies' stock symbol?

Taysha Gene Therapies trades on the NASDAQ under the ticker symbol "TSHA."

When did the company's lock-up period expire?

Taysha Gene Therapies' lock-up period expired on Tuesday, March 23rd. Taysha Gene Therapies had issued 7,869,566 shares in its initial public offering on September 24th. The total size of the offering was $157,391,320 based on an initial share price of $20.00. Since the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

How do I buy shares of Taysha Gene Therapies?

Shares of TSHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Taysha Gene Therapies' stock price today?

One share of TSHA stock can currently be purchased for approximately $23.86.

How much money does Taysha Gene Therapies make?

Taysha Gene Therapies has a market capitalization of $900.98 million.

How many employees does Taysha Gene Therapies have?

Taysha Gene Therapies employs 38 workers across the globe.

What is Taysha Gene Therapies' official website?

The official website for Taysha Gene Therapies is www.tayshagtx.com.

Where are Taysha Gene Therapies' headquarters?

Taysha Gene Therapies is headquartered at 2280 Inwood Road, DALLAS TX, 75235.

How can I contact Taysha Gene Therapies?

Taysha Gene Therapies' mailing address is 2280 Inwood Road, DALLAS TX, 75235. The company can be reached via phone at 214-612-0000 or via email at [email protected]

This page was last updated on 4/17/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here